Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593759 · ClinicalTrials.gov registry record · Phase 3
Cardiac Sarcoidosis Randomized Trial
A Phase 3 study of Sarcoidosis and Cardiac Sarcoidosis, sponsored by Ottawa Heart Institute Research Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT03593759 is a Phase 3 study of Sarcoidosis and Cardiac Sarcoidosis that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 194 participants, below the 2,160-participant average among 21 other Sarcoidosis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03593759, a Phase 3 study of Sarcoidosis and Cardiac Sarcoidosis, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Conditions Studied
Interventions
- DRUG Methotrexate
- DRUG Prednisone or Prednisolone
Study Locations (20)
Quebec
- Montreal Heart Institute - Montreal
- CIUSSS-Hopital du Sacre-Coeur de Montreal - Montreal
- Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval - Québec
- CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont - Sherbrooke
Ontario
- St. Joseph's Healthcare Centre - Hamilton
- London Health Sciences Centre - London
- University of Ottawa Heart Institute - Ottawa
Connecticut
- Yale-New Haven Hospital - New Haven
Massachusetts
- Tufts Medical Center - Boston
Michigan
- University of Michigan-Michigan Medicine Cardiovascular Center - Ann Arbor
Minnesota
- University of Minnesota - Minneota
New York
- Montefiore Medical Center - New York
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03593759
The ClinicalTrials.gov registry entry for NCT03593759 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,160-participant average among 21 other Sarcoidosis trials with a reported enrollment target (91% lower). The listed sponsor is Ottawa Heart Institute Research Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate is the first listed.
NCT03593759 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Quebec, Ontario, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03593759 about?
NCT03593759 is a clinical study titled "Cardiac Sarcoidosis Randomized Trial". Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low do...
What is the current status of trial NCT03593759?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2019-01-15. Estimated completion is 2025-12.
What conditions does trial NCT03593759 study?
This clinical trial studies the following conditions: Sarcoidosis, Cardiac Sarcoidosis.
What interventions are being tested in trial NCT03593759?
The interventions under investigation include: Methotrexate (DRUG), Prednisone or Prednisolone (DRUG).
Who is sponsoring clinical trial NCT03593759?
This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03593759 being conducted?
This trial has 20 study locations across Connecticut, Massachusetts, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
RECRUITING
-
Vitamin D Homeostasis in Sarcoidosis
RECRUITING · Phase 4
-
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.